As they have same origin, these hormones share some similarities, and hence the name ”glucagon-like”. The major sources of GLP-1 are the L-cells in the lining of small intestine.

Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser (2)]exendin ...

COMMENTARY Glucagon-like Peptide 1: Incretin, Glucose Regulatory Hormone, and Diabetes Treatment, Part II Torsten P. Vahl, MD; David A. D'Alessio MD Disclosures May 07, 2004 0 ...

Overview of Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes Richard E. Pratley, MD Disclosures Medscape J Med. 2008;10 (7):171 0 ...

Novel Glucagon like peptide-1 (GLP-1) drugs were designed and industrial prepared by researchers from Hefei Institutes of Physical Science, Chinese Academy of Sciences Through molecular design ...

The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued ...

Correspondence Glucagon-like Peptide 1–Receptor Scans to Localize Occult Insulinomas Published August 14, 2008 N Engl J Med 2008;359: 766 - 768 DOI: 10.1056/NEJMc0802045 ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

Glucagon-like peptide-1 receptor agonists related to adolescent weight loss, study suggests Date: February 4, 2013 Source: American Medical Association (AMA) Summary: Preliminary evidence from a ...